Media headlines about Agios Pharmaceuticals (NASDAQ:AGIO) have been trending somewhat positive on Saturday, according to Accern. Accern ranks the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Agios Pharmaceuticals earned a daily sentiment score of 0.15 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 45.4989317303248 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the news articles that may have impacted Accern Sentiment Analysis’s analysis:
- Shares Seesawing on Volume: Agios Pharmaceuticals Inc (AGIO) – Sheridan Daily (sheridandaily.com)
- Agios Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AGIO-US : August 18, 2017 (finance.yahoo.com)
- Agios Pharmaceuticals, Inc. (AGIO) Given Consensus Recommendation of “Buy” by Brokerages (americanbankingnews.com)
- Diehard Bargain Hunter: Forum Energy Technologies, Inc. (FET), Agios Pharmaceuticals, Inc. (AGIO) – AllStockNews (allstocknews.com)
- These business leaders have resigned from President Trump’s special council (fishinghd.com)
AGIO has been the topic of several analyst reports. BidaskClub cut Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, August 9th. Oppenheimer Holdings, Inc. set a $75.00 price target on Agios Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, June 1st. Canaccord Genuity set a $90.00 price target on Agios Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, August 8th. Janney Montgomery Scott cut Agios Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Monday, June 26th. Finally, Cann reaffirmed a “buy” rating and issued a $75.00 target price on shares of Agios Pharmaceuticals in a report on Sunday, June 11th. Five research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $74.75.
Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.78) earnings per share for the quarter, missing the consensus estimate of ($1.57) by $0.21. Agios Pharmaceuticals had a negative return on equity of 68.15% and a negative net margin of 502.12%. The company had revenue of $11.30 million for the quarter, compared to analyst estimates of $10.68 million. During the same quarter last year, the company earned ($1.47) EPS. The firm’s revenue for the quarter was up 62.1% on a year-over-year basis. Equities analysts expect that Agios Pharmaceuticals will post ($7.07) EPS for the current year.
In related news, CEO David P. Schenkein sold 27,000 shares of the company’s stock in a transaction dated Wednesday, August 2nd. The shares were sold at an average price of $59.95, for a total transaction of $1,618,650.00. Following the completion of the transaction, the chief executive officer now owns 3,000 shares in the company, valued at approximately $179,850. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Lewis Clayton Jr. Cantley sold 2,000 shares of the company’s stock in a transaction dated Wednesday, June 14th. The shares were sold at an average price of $50.87, for a total transaction of $101,740.00. Following the sale, the director now directly owns 90,197 shares of the company’s stock, valued at approximately $4,588,321.39. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 79,120 shares of company stock valued at $4,557,207. Insiders own 10.55% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Agios Pharmaceuticals (NASDAQ:AGIO) Getting Somewhat Favorable Press Coverage, Report Shows” was first reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at https://www.com-unik.info/2017/08/19/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-agios-pharmaceuticals-nasdaqagio-share-price-updated-updated.html.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
What are top analysts saying about Agios Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Agios Pharmaceuticals Inc. and related companies.